WallStSmart

Berkshire Hathaway Inc (BRK-A)vsPfizer Inc (PFE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Berkshire Hathaway Inc generates 493% more annual revenue ($375.39B vs $63.32B). BRK-A leads profitability with a 19.3% profit margin vs 11.8%. BRK-A appears more attractively valued with a PEG of 9.95. BRK-A earns a higher WallStSmart Score of 59/100 (C).

BRK-A

Buy

59

out of 100

Grade: C

Growth: 6.7Profit: 6.5Value: 5.0Quality: 8.5
Piotroski: 4/9Altman Z: 2.46

PFE

Buy

55

out of 100

Grade: C

Growth: 3.3Profit: 7.0Value: 5.3Quality: 4.8
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BRK-A.

PFEUndervalued (+29.4%)

Margin of Safety

+29.4%

Fair Value

$37.48

Current Price

$25.68

$11.80 discount

UndervaluedFair: $37.48Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BRK-A6 strengths · Avg: 9.2/10
Market CapQuality
$1.03T10/10

Mega-cap, among the largest globally

Price/BookValuation
1.4x10/10

Reasonable price relative to book value

EPS GrowthGrowth
119.6%10/10

Earnings expanding 119.6% YoY

Debt/EquityHealth
0.219/10

Conservative balance sheet, low leverage

P/E RatioValuation
14.2x8/10

Attractively priced relative to earnings

Free Cash FlowQuality
$5.45B8/10

Generating 5.5B in free cash flow

PFE4 strengths · Avg: 8.8/10
Operating MarginProfitability
31.6%10/10

Strong operational efficiency at 31.6%

Market CapQuality
$150.92B9/10

Large-cap with strong market position

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$2.18B8/10

Generating 2.2B in free cash flow

Areas to Watch

BRK-A2 concerns · Avg: 3.0/10
Revenue GrowthGrowth
4.4%4/10

4.4% revenue growth

PEG RatioValuation
9.952/10

Expensive relative to growth rate

PFE3 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
13.772/10

Expensive relative to growth rate

EPS GrowthGrowth
-10.1%2/10

Earnings declined 10.1%

Comparative Analysis Report

WallStSmart Research

Bull Case : BRK-A

The strongest argument for BRK-A centers on Market Cap, Price/Book, EPS Growth. Profitability is solid with margins at 19.3% and operating margin at 14.3%.

Bull Case : PFE

The strongest argument for PFE centers on Operating Margin, Market Cap, Price/Book.

Bear Case : BRK-A

The primary concerns for BRK-A are Revenue Growth, PEG Ratio.

Bear Case : PFE

The primary concerns for PFE are Piotroski F-Score, PEG Ratio, EPS Growth.

Key Dynamics to Monitor

BRK-A carries more volatility with a beta of 0.62 — expect wider price swings.

PFE is growing revenue faster at 5.4% — sustainability is the question.

BRK-A generates stronger free cash flow (5.5B), providing more financial flexibility.

Monitor INSURANCE - DIVERSIFIED industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BRK-A scores higher overall (59/100 vs 55/100), backed by strong 19.3% margins. PFE offers better value entry with a 29.4% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Berkshire Hathaway Inc

FINANCIAL SERVICES · INSURANCE - DIVERSIFIED · USA

Berkshire Hathaway Inc. is an American multinational conglomerate holding company headquartered in Omaha, Nebraska, United States. The company wholly owns GEICO, Duracell, Dairy Queen, BNSF, Lubrizol, Fruit of the Loom, Helzberg Diamonds, Long & Foster, FlightSafety International, Pampered Chef, Forest River, and NetJets, and also owns 38.6% of Pilot Flying J; and significant minority holdings in public companies Kraft Heinz Company (26.7%), American Express (18.8%), The Coca-Cola Company (9.32%), Bank of America (11.9%), and Apple (6.3%).

Visit Website →

Pfizer Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.

Visit Website →

Want to dig deeper into these stocks?